Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Nail clipping may not be sufficient to corroborate the diagnosis of psoriasis.","authors":"L Bertanha, N G Di Chiacchio, N Di Chiacchio, M L Cintra","doi":"10.1111/jdv.20414","DOIUrl":"https://doi.org/10.1111/jdv.20414","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consensus versus discordance in the classification of borderline melanocytic lesions between dermatopathologists and artificial intelligence: An Australian cohort study.","authors":"Nicholas M Muller, Chantal Rutjes, Samuel X Tan, Nisal Vipulaguna, Ayooluwatomiwa Oloruntoba, Toan Nguyen, Lena von Schuckmann, Brigid Betz-Stablein, Kiarash Khosrotehrani, Zongyuan Ge, H Peter Soyer, Ian Katz","doi":"10.1111/jdv.20412","DOIUrl":"https://doi.org/10.1111/jdv.20412","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancement of sun-damaged skin qualities with tirbanibulin: A prospective Phase 4 study (SunDamage Study).","authors":"Daisy Kopera","doi":"10.1111/jdv.20416","DOIUrl":"https://doi.org/10.1111/jdv.20416","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intratumoural programmed cell death protein expression in 92 patients with atypical fibroxanthoma and pleomorphic dermal sarcoma.","authors":"Thilo Gambichler, Emilia Sorescu, Fahimeh Razeghpour, Jürgen C Becker, Laura Susok","doi":"10.1111/jdv.20421","DOIUrl":"https://doi.org/10.1111/jdv.20421","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Low-dose isotretinoin for the management of rosacea: A systematic review and meta-analysis'.","authors":"Ankur Kapoor, Rachana Mehta, Muhammed Shabil, Sanjit Sah","doi":"10.1111/jdv.20394","DOIUrl":"https://doi.org/10.1111/jdv.20394","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.","authors":"Z Apalla, A Freites-Martinez, K Grafanaki, A Ortiz-Brugues, V Nikolaou, D Fattore, P Sollena, S Deverapalli, S Babakoohi, A Galimont, N Kluger, M Beylot-Barry, C Larocca, C Iriarte, J Smith, I Tattersall, R Dodiuk-Gad, M Sauder, C Carrera, B Kwong, M Whitley, N Leboeuf, P Romano, M Starace, V Mateeva, J Riganti, J Hirner, A B Patel, C M Reyes-Habito, L Kraehenbuehl, M Kheterpal, M Fida, J Hassel, M Lacouture, V Sibaud","doi":"10.1111/jdv.20391","DOIUrl":"https://doi.org/10.1111/jdv.20391","url":null,"abstract":"<p><strong>Background: </strong>There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.</p><p><strong>Objective: </strong>To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.</p><p><strong>Methods: </strong>The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia. The questionnaire consisted of 84 statements in total, regarding diagnosis and treatment of EGFRi-induced acneiform rash. Experts responded to an anonymous 5-point Likert scale survey. The coordinators collected the first-round responses that were checked for consensus (≥75% agreement in positive [agree or strongly agree] or in negative [disagree or strongly disagree] vote). The statements that did not reach strong consensus in the first round were revised, according to experts' feedback, for a second-round survey.</p><p><strong>Results: </strong>Strong consensus was reached in 75/84 (89.3%) of the statements, whilst moderate consensus was achieved in 6/84 elements. Key points include consideration of low-dose isotretinoin for refractory grade II/III acneiform rash, use of topical steroid-sparing agents like topical pimecrolimus in the maintenance phase and use of doxycycline in either 100 or 200 mg per day as prophylactic treatment. Interestingly, experts did not recommend topical antibiotics, neither for prevention, nor for treatment. Consensus failure in 3/84 objects is mostly related to the lack of robust data on these topics.</p><p><strong>Conclusion: </strong>This consensus offers crucial insights often overlooked by radiotherapists, general practitioners, dermatologists and oncologists, and it is expected to improve the management of oncologic patients treated with EGFRi in different settings and continents.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute urticaria management: Gaps, challenges and the need for further evidence","authors":"Emek Kocatürk,&nbsp;Marcus Maurer","doi":"10.1111/jdv.20320","DOIUrl":"10.1111/jdv.20320","url":null,"abstract":"&lt;p&gt;The recent systematic review published in JEADV by Badloe et al&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; provides a comprehensive analysis of the management for acute urticaria (AU) with corticosteroids, highlighting the persistent uncertainties surrounding the use of systemic corticosteroids in conjunction with antihistamines. This article offers valuable insights into the current practices and evidence-based approaches, yet it underscores significant gaps that necessitate further research.&lt;/p&gt;&lt;p&gt;Despite limited robust evidence supporting their efficacy, corticosteroids are conventionally and widely used in the treatment of AU. The contrasting findings from the studies included in this review reflect the clinical conundrum faced by healthcare providers: while corticosteroids are commonly employed to manage AU, their benefits in conjunction with antihistamines remain unsubstantiated in many cases. For instance, out of four RCTs which assessed the efficacy of corticosteroids in addition to antihistamines for the management of AU, two studies revealed that a combination of corticosteroids and antihistamines did not have a beneficial effect on the resolution of AU, while the other two found a positive effect.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The effect of corticosteroids in the management of urticaria has been recently evaluated in a systematic review by Chu et al&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; which provided moderate certainty of evidence that systemic corticosteroids likely improve urticaria activity in patients who do not respond well to antihistamines alone; however, systemic corticosteroids likely increase the risk of adverse effects such as GI discomfort and neuropsychiatric changes, with an odds ratio (OR) of 2.76. As a result, it is concluded that the addition of corticosteroids to an antihistamine as a treatment option for AU and to assess long-term outcomes of corticosteroid treatment needs to be further investigated.&lt;/p&gt;&lt;p&gt;The article also highlights a critical issue: the reliance on older treatment modalities, such as first-generation antihistamines, which are still prevalent in many emergency departments. The sedative properties and other adverse effects of these drugs, particularly diphenhydramine, raise concerns about their continued use when less sedative and rapid acting options like cetirizine are available. The finding that intravenous cetirizine is as effective as diphenhydramine, with fewer side effects, suggests a potential shift in treatment protocols that could enhance patient outcomes and safety.&lt;/p&gt;&lt;p&gt;The review also brings to light the current gaps of knowledge in AU such as the potential for AU to progress to chronic spontaneous urticaria (CSU) and whether corticosteroids might influence this progression. Previous reports show that average duration of AU is ≤1 week and the rates of progression of AU to CSU are between 5% and 39%.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Two previous studies tried to identify the factors that are linked to the progression of AU to ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2047-2048"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combining treat-to-target principles with patient choice: A small step AHEAD in the right direction","authors":"Hywel C. Williams","doi":"10.1111/jdv.20298","DOIUrl":"10.1111/jdv.20298","url":null,"abstract":"&lt;p&gt;The treat-to-target approach specifies optimum treatment targets such as blood glucose levels that result in health benefit. Setting single targets for complex inflammatory conditions such as atopic dermatitis (AD) is challenging, and depends on which disease aspects disease are considered to be important, by whom, along with how and when to measure them. A criticism of treat-to-target is its one-size-fits-all approach. Patients/carers may have different preferences on what is important for them, and what is a worthwhile gain when traded-off against the harms and inconvenience of particular treatments.&lt;/p&gt;&lt;p&gt;To address these limitations of a treat-to-target approach, the AHEAD (Aiming High in Eczema/Atopic Dermatitis) international group sought to identify &lt;i&gt;what&lt;/i&gt; aspects of atopic dermatitis (AD) might be included in a treat-to-target approach and &lt;i&gt;how&lt;/i&gt; they might be measured.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The group's previous survey identified the most significant symptoms for adult AD patients, how they are measured and treatment expectations. The group used that data to draft a series of treatment recommendations that were subject to a Delphi survey involving 77 AD experts. Unusually, consensus was reached for all 34 recommendations after just one voting round. The group suggest that patients should identify between one to three from six features selected by the AD experts (itch, skin appearance, sleep disturbance, mental health, skin pain and daily life impact). The clinician also chooses an additional objective assessment of disease control. Targets for both optimal and moderate control are suggested for these outcomes for 3–6 months, and monitored with a recommended instrument chosen by the clinician.&lt;/p&gt;&lt;p&gt;What I liked about this initiative was the attempt to combine the best of both worlds—retaining more ambitious treatment targets for people with AD with some input from patients on what to measure and how. The proposed outcomes align with clinical practice outcomes from the Harmonising Outcomes Measures for Eczema (HOME) initiative.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; I also liked the flexibility for moderate as well as optimal control.&lt;/p&gt;&lt;p&gt;What was missing was lack of consideration of other crucial aspects that govern treatment choices for patients including adverse effects, inconvenience, access and costs. Although adverse effects may be treatment-specific, balancing benefits and harms is a mandatory part of shared decision-making as exemplified in AD patient decision aids.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; The preceding adult patient qualitative work, sponsored by AbbVie and cited only in abstract form, was useful but limited, as young people and children/carers where AD is commonest were not included. Although the adult qualitative study was considered when drafting the initial AHEAD recommendations, the complete absence of patient/carer involvement in the final recommendations was disappointing. Other initiatives such as HOME have found that ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2051-2052"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor's Picks November 2024","authors":"","doi":"10.1111/jdv.20337","DOIUrl":"10.1111/jdv.20337","url":null,"abstract":"&lt;p&gt;Although acute urticaria (AU) is highly prevalent (Figure 1), limited evidence and recommendations exist. According to a review by Badloe et al., corticosteroid addition to a second-generation oral H1-antihistamine did not improve acute urticaria symptoms in two out of three RCTs, and combination of a first-generation H1-antihistamine and H2-antihistamine (intravenously) was most effective for urticaria relief in two out of five studies.&lt;/p&gt;&lt;p&gt;Emek Kocatürk&lt;/p&gt;&lt;p&gt;Badloe FMS, Grosber M, Ring J, Kortekaas Krohn I, Gutermuth J. Treatment of acute urticaria: a systematic review. &lt;i&gt;J Eur Acad Dermatol Venereol&lt;/i&gt; 2024;38:2082–2092. https://doi.org/10.1111/jdv.19904.&lt;/p&gt;&lt;p&gt;Chronic Nodular Prurigo (CNPG) is a pruritic skin condition with frequent comorbidities, characterized by the development of nodules due to scratching.&lt;/p&gt;&lt;p&gt;Pereira et al. evaluated the association between clinically relevant comorbidities (e.g. diabetes and hypertension), itch intensity, and quality of life (QoL) impairment in 513 adults with CNPG treated in 12 European countries (Figure 2). Conditions not typically involved in the pathophysiology of itch also appeared to be related to the perception of itch. Careful management of comorbidities in patients with CNPG is important to potentially alleviate itch intensity and improve QoL.&lt;/p&gt;&lt;p&gt;Pereira MP, Gutsche A, Weisshaar E, et al. Chronic nodular prurigo: association between comorbidities, itch and quality of life. &lt;i&gt;J Eur Acad Dermatol Venereol&lt;/i&gt; 2024;38:e984–e988. https://doi.org/10.1111/jdv.20038.&lt;/p&gt;&lt;p&gt;International expert dermatologists drafted the Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations, suggesting that disease severity should be assessed using both physician-reported and patient-reported outcomes. Physicians should discuss results with patients/caregivers, aiming for targets to optimize patient outcomes. The ultimate treatment goal is a satisfied patient with minimal impact on QoL, clear/almost-clear skin, and no/minimal itch.&lt;/p&gt;&lt;p&gt;They also established a novel, patient-centred, minimal disease activity (MDA) concept, where patients/caregivers choose one to three atopic dermatitis symptoms/features most important to them, physicians select corresponding patient-reported outcome measures, and both discuss optimal targets (Figure 3).&lt;/p&gt;&lt;p&gt;Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. &lt;i&gt;J Eur Acad Dermatol Venereol&lt;/i&gt; 2024;38:2139–2148. https://doi.org/10.1111/jdv.20229.&lt;/p&gt;&lt;p&gt;Vindenes et al. assessed the understudied relationship between the microbiome and self-reported hand eczema, hand hygiene practices, and moisturizer use. Individuals with hand eczema (HE) showed a more dysbiotic bacterial community over time, with an increase in Staphylococcus associated with active HE. Frequent hand washing","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2043-2044"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of hand eczema","authors":"P. V. Chernyshov","doi":"10.1111/jdv.20296","DOIUrl":"10.1111/jdv.20296","url":null,"abstract":"&lt;p&gt;Hand eczema (HE) is a widespread chronic inflammatory skin disease often with multiple provoking factors (e.g. professional), subjective complaints and with lesions located on visible areas. All of these lead to a severe negative impact of HE on patients' lives. Siewertsen et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; have presented the results of a systematic review and meta-analysis on anxiety, depression and quality of life impairment in patients with HE.&lt;/p&gt;&lt;p&gt;The authors&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; were concerned that different measures of HE severity, quality of life and depression were used across their selected studies, complicating comparability. However the same dermatology-specific quality of life instrument, the Dermatology Life Quality Index (DLQI), was used in 82% of their included studies. The DLQI is the most widely used QoL instrument in dermatology both for general use and in the majority of individual skin diseases. Many national and international guidelines recommend QoL assessment in dermatology and some of them contain detailed recommendations on treatment goals and changes of treatment approaches based on DLQI score banding and minimal clinically important difference (MCID).&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The meta-analysis by Siewertsen et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; revealed that the mean DLQI scores of patients with HE corresponds to the lower range of the ‘very large effect on patient's life’ DLQI score band meaning descriptors. Interpretation of the scores and the ‘minimally important change’ for a disease-specific quality of life instrument for hand eczema (QOLHEQ) have been proposed.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; However, as pointed out by Siewertsen et al.,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; to date only a few studies have used this instrument.&lt;/p&gt;&lt;p&gt;In patients with HE, scores of various disease severity measures correlated significantly with quality of life impairment scores, using the DLQI. This is also seen in other chronic inflammatory skin diseases. Generic health-related quality of life instruments may be used in any disease and in healthy individuals. The EuroQol-5D visual analogue scale scores demonstrated more impaired QoL in HE patients than in healthy controls, as did the separate domain scores of the Short Form-36.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Siewertsen et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; mentioned among the limitations of their systematic review that they were not able to assess differences between male and female patients. However, a large international multicentre study previously demonstrated that only female patients with HE had higher scores for depression and anxiety than controls.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; In this context it is especially interesting that the meta-analysis by Siewertsen et al.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; revealed significantly higher levels of anxiety in HE patients than in controls, but similar levels of depression.&lt;/p&gt;&lt;p&gt;Data on the association between HE and suicidal ideation when comparing patients with HE with he","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2049-2050"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}